

Development Data

MAMaZ Against Malaria at Scale



Project Purpose

Increasing access to pre-referral rectal artesunate (RAS)—a lifesaving drug administered immediately upon diagnosis of malaria in children.

Designed to Achieve

- Procurement/distribution of RAS via public- and private-sector partnerships
- Training community health volunteers (CHVs) on diagnosis of severe malaria, delivery of RAS
- · Emergency patient transport via system of bicycle "ambulances"
- · Innovation with strong gender equality (GE) approach





Children aged 2 months to 6 years receiving RAS to date Over 2,900 CHVs trained in

RAS administration and referral to date

Expected by 2030

Up to 138,000 lives improved of children receiving RAS, with timely transportation to health facility and administration of injectable artesunate

